2022 Stronger - PH337 - The Importance, Implementation and Optimization of Biosimilars: Proven Strategies - On Demand

This session features a panel of health care leaders who will share their experiences and insights into the implementation, use and management of biosimilars.

The pharmacy team at Baptist Cancer Center (BCC) has been successful in optimizing biosimilar use across 17 outpatient oncology offices. In fiscal year 2021, the BCC pharmacy surpassed its goal by increasing overall biosimilar utilization from 58% to 79% — saving $9 million in drug purchase expense. BCC also successfully converted first-to-market biosimilars to newer, lower-priced products.

Biologics are one of the highest expenses at Sharp HealthCare, representing over 40% of pharmaceutical spend. With few opportunities to optimize savings in the treatment of chronic diseases and cancers, the Infusion Center and Pharmacy Workgroup formed to expand the use of biosimilars. The group was successful due to multidisciplinary collaboration; provider education; and standardized, efficient processes. Biosimilar use is above 90%, resulting in a $6 million cost savings in two years.

Froedtert & the Medical College of Wisconsin has successfully addressed challenges around the use of biosimilars, such as prescriber and patient misperceptions, variability in insurance coverage, and revenue cycle complexities — all of which make biosimilar adoption more difficult to achieve. Leaders will describe a novel strategy to address these challenges by expediting formulary inclusion of biosimilars and maximizing their value for patients and the health system. Interdisciplinary collaboration, leadership support and pharmacy revenue assessment are important for initiative success.

Join this session to learn how to optimize the use of biosimilars at your organization.

Target Audience

  • Pharmacists
  • Other Healthcare Professionals

Learning Objectives

Describe how to design a process for biosimilar implementation and utilization across the health system.

Explain the barriers to and challenges of implementing a biosimilar conversion process within an integrated health care system.

List various metrics needed to maintain and monitor success of the biosimilar conversion process.

Additional Information

AttachmentSize
PDF icon PH337.pdf1.82 MB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 General CE – Attendance
Course opens: 
09/14/2022
Course expires: 
09/21/2023

Faculty

Alexander Quesenberry, PharmD, BCOP, Director of Pharmacy, Baptist Memorial Health Care Corp/Baptist Cancer Center, Memphis, TN

Susan Sachs, PharmD, Manager of Pharmacy Finance and Regulatory Compliance, Sharp HealthCare, San Diego, CA

Nilay Pradhan, PharmD, BCACP, Senior Specialist, Pharmacy Contracts, Sharp HealthCare, San Diego, CA

Adam Biggs, PharmD, Pharmacist, Center for Medication Utilization, Froedtert Health, Milwaukee, WI

Shannon Werner, PharmD, Coordinator, Center for Medication Utilization, Froedtert Health, Milwaukee, WI

Disclosure

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
 
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
 
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
 
FDA Off-Label Use
 
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
 
Disclosure Statements
 
Absence of Relevant Financial Relationships
 
None of the planners, faculty, or others in a position to control content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Accreditation Statement

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
 
 

Credit Types

 

Pharmacists (CPE)

Vizient, Inc. designates this enduring material for a maximum of 1.0 contact hours for Pharmacists. 

Universal Activity Number: JA0006103-0000-22-093-H04-P

Other Healthcare Professionals (General CE Credit)

Vizient, Inc. will award a maximum of 1.0 contact hours to all other healthcare professionals who successfully complete the activity. These individuals will receive a Certificate of Participation indicating the maximum credits available.

Many state licensing boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

 

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 General CE – Attendance
Please login or register to take this course.

 

Select the Obtain Credit button to access the activity.